MET and neutropenia: Crizotinib is a tyrosine kinase inhibitor of ALK, MET, and ROS1 kinases.10 Commonly reported adverse effectsinclude nausea, vomiting, diarrhea, constipation, fatigue, transient visualdisorders, peripheral edema, and neutropenia.